Radiation Therapy in Multiple Myeloma

2010 ◽  
pp. 91-100 ◽  
Author(s):  
Joel S. Greenberger
Keyword(s):  
Multiple Myeloma ◽  
Radiation Therapy

Utilization of radiation therapy in multiple myeloma: trends and changes in practice

2021 ◽  
Author(s):  
Sikander Ailawadhi ◽  
Ryan Frank ◽  
Meghna Ailawadhi ◽  
Zahara Kanji ◽  
Prachi Jani ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Radiation Therapy

Feasibility and Efficacy of Local Radiation Therapy With Concurrent Novel Agents in Patients With Multiple Myeloma

2013 ◽  
Vol 87 (2) ◽  
pp. S556
Author(s):  
S. Shin ◽  
R. Chouake ◽  
N. Sanfilippo ◽  
A. Mazumder ◽  
J. Silverman
Keyword(s):  
Multiple Myeloma ◽  
Radiation Therapy ◽  
Novel Agents ◽  
Local Radiation

scholarly journals Radiation Therapy for Solitary Plasmacytoma and Multiple Myeloma: Guidelines From the International Lymphoma Radiation Oncology Group

2018 ◽  
Vol 101 (4) ◽  
pp. 794-808 ◽  
Author(s):  
Richard W. Tsang ◽  
Belinda A. Campbell ◽  
Jayant S. Goda ◽  
Chris R. Kelsey ◽  
Youlia M. Kirova ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Radiation Therapy ◽  
Radiation Oncology ◽  
Solitary Plasmacytoma ◽  
Oncology Group ◽  
Radiation Oncology Group

SUCCESSFUL MANAGEMENT OF SPHENOID RELAPSE OF MULTIPLE MYELOMA WITH RADIATION THERAPY: A CASE REPORT

2021 ◽  
pp. 1-2
Author(s):  
A. Bazine ◽  
M. Torreis ◽  
M. Elmarjany ◽  
M. Benlemlih ◽  
A. Maghous ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Bone Marrow ◽  
Radiation Therapy ◽  
Case Report ◽  
Skull Base ◽  
Plasma Cells ◽  
Complete Disappearance ◽  
Successful Management ◽  
Shed Light

Multiple myeloma (MM) is typically characterized by neoplastic proliferation of plasma cells in the bone marrow and can result in extensive skeletal destruction. Involvement of skull base is extremely rare, especially sphenoid bone. We report in this work the case of a 62-year-old woman, who presented with a sphenoid relapse of multiple myeloma treated with radiation therapy, with signicant clinical improvement and almost complete disappearance of the sphenoid metastasis. We shed light, through this case, on the rarity of sphenoid metastases in multiple myeloma and on the role of radiotherapy in the management of this type of location.

Boost of Immune Responses Against NY-ESO-1 Following Local Radiation Therapy in Patients with Multiple Myeloma: A Potential Contribution to Tumor Immunosurveillance

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4512-4512
Author(s):  
Miriam Alb ◽  
Jörg Tamihardja ◽  
Erdwine Klinker ◽  
Martin Schreder ◽  
Stefan Knop ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Radiation Therapy ◽  
T Lymphocytes ◽  
Immune Responses ◽  
Mrna Expression ◽  
Tumor Immunity ◽  
Protein Level ◽  
Mrna Levels ◽  
Hematopoietic Stem ◽  
Local Radiation

Abstract Introduction Local radiation therapy (RT) is commonly employed to treat bone lesions and/or extramedullary manifestations of multiple myeloma (MM) or solitary bone plasmacytoma (SBP). Besides providing sufficient control of local tumor growth, radiation therapy may also contribute to broader anti-tumor immunity by generating off-site cellular immune responses. Here, we put a focus on tumor-associated antigens (TAAs) well known for their expression in MM such as Wilms' Tumor Protein 1 (WT1), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), human telomerase reverse transcriptase (hTERT), mucin 1 (MUC1), and preferentially expressed antigen of melanoma (PRAME) and assessed CD8-mediated immune responses before and during radiation. Methods We prospectively recruited HLA-A*02:01-positive patients with multiple myeloma or solitary plasmacytoma requiring local radiation therapy for bone and extramedullary lesions in this scientific, non-interventional study, supported by a grant of the Wilhelm Sander Foundation, Germany, and approved by our local ethical committee. All patients provided written informed consent. Immune responses against HLA-A*02:01-restricted peptides of WT1, NY-ESO-1, hTERT, MUC1, and PRAME were assessed at three different time points: prior to RT, end of RT and six to eight weeks after RT. CD8+ T lymphocytes were isolated from peripheral blood and stimulated with irradiated, peptide-pulsed T2 cells (174 x CEM.T2; ATCC® CRL-1992™). After extraction of total RNA, Interferon gamma (IFNγ) mRNA expression was analyzed by RT-qPCR. IFNγ mRNA levels were normalized to CD8 mRNA levels. IFNγ mRNA expression of cells stimulated with the irrelevant melanoma antigen Glycoprotein 100 (gp100) served as calibrator. An expression level of 2.0 or more as compared to gp100 was considered as a positive result. Furthermore, an intracellular cytokine staining assay to detect IFNγ release in peptide-stimulated cells was employed to confirm PCR results on a protein level. Peptide-pulsed T2 cells also served as targets in CD107a degranulation assays. Results To date, 19 patients including 16 MM and three SBP patients received fractionated local RT with or without concomitant systemic therapy. 13 patients were previously untreated; three patients received prior allogeneic and five prior autologous hematopoietic stem cell transplantation. At baseline, positive immune responses were frequently detected against NY-ESO-1 (10 out of 17 assessed patients; 58.8%) but interestingly not against hTERT, WT1, MUC1 or PRAME (see Figure). Consequently, baseline immune responses against NY-ESO-1 were significantly higher (p<0.001) as compared to all other TAAs investigated (Kruskal Wallis test). These median response levels against NY-ESO-1 further increased in the course of radiation therapy and were confirmed by flow cytometry on a protein level. The functionality and specificity of these responses could be demonstrated in degranulation assays suggesting the ability to deliver efficient anti-tumor immunity. Conclusions Immunity against NY-ESO-1 was preexisting in the majority of patients and was undergoing marked expansion under local radiotherapy. This phenomenon was not found for any other TAA investigated suggesting that NY-ESO-1 carries a unique immunogenicity justifying most recent attempts to employ NY-ESO-1 as a target for genetically engineered T lymphocytes. Finally, this tumor-specific immunity is likely to contribute to immunosurveillance of multiple myeloma additionally supported by immune modulatory drugs applied for treatment such as IMiDs and proteasome inhibitors. FIgure FIgure. Disclosures Knop: Takeda: Consultancy. Einsele:Celgene: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Novartis: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Speakers Bureau. Mielke:MSD: Consultancy, Other: Travel grants; Gilead: Other: Travel grants; Novartis: Consultancy; Celgene: Other: Travel grants, Speakers Bureau; JAZZ Pharma: Speakers Bureau.

scholarly journals Local Radiation Therapy for Palliation in Patients With Multiple Myeloma of the Spine

2017 ◽  
Vol 99 (2) ◽  
pp. E432
Author(s):  
D.J. Mark ◽  
R. Meshrekey ◽  
E.E. Klein ◽  
M. Ghaly
Keyword(s):  
Multiple Myeloma ◽  
Radiation Therapy ◽  
Local Radiation

Radiation Therapy in Multiple Myeloma

Radiology ◽  
1975 ◽  
Vol 115 (1) ◽  
pp. 175-178 ◽  
Author(s):  
William B. Mill
Keyword(s):  
Multiple Myeloma ◽  
Radiation Therapy

scholarly journals Long‐term effects of localized spinal radiation therapy on vertebral fractures and focal lesions appearance in patients with multiple myeloma

1997 ◽  
Vol 96 (4) ◽  
pp. 743-745 ◽  
Author(s):  
FREDERIC LECOUVET ◽  
FRANC¸OISE RICHARD ◽  
BRUNO VANDE BERG ◽  
JACQUES MALGHEM ◽  
BAUDOUIN MALDAGUE ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Radiation Therapy ◽  
Vertebral Fractures ◽  
Long Term Effects ◽  
Focal Lesions
Sign in / Sign up

Export Citation Format

Share Document